Stock Track | Novavax Plummets 5.04% as FDA Links COVID Vaccines to Child Deaths, Tightens Approval Rules

Stock Track12-02

Novavax Inc. (NVAX) shares plummeted 5.04% during intraday trading on Monday, underperforming the broader market as vaccine stocks faced heavy selling pressure.

The decline followed a memo from the U.S. Food and Drug Administration (FDA) linking COVID-19 vaccinations to the deaths of at least 10 children due to heart inflammation. The FDA's top vaccine regulator, Dr. Vinay Prasad, announced plans to tighten approval standards for vaccines, including requiring larger clinical studies and stricter oversight. This regulatory shift has raised concerns about future vaccine sales and approvals for Novavax, which relies heavily on its COVID-19 vaccine for revenue.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment